CLINICAL PATHOLOGY ASSOCIATES

1150 North 18th STE 102 Abilene, TX, 79601, 325-670-6500 1-800-478-9341, CLIA 45D0508312

LAB REPORT

Accession #: OP2099999

Patient: DUCKOP, DONALD

DOB: 1/20/1980 Age: 39 Sex: Female

Specimen Date: 1/17/2020

Date Received: 1/18/2020

Date Printed: 11/12/2024

JAMES I. DUFF, M.D.
1150 N. 18TH, STE 102
ABILENE, TX 79601

Physician(s): JAMES I DUFF, M.D.

Chart #:

LMP: N/A **TEST:** MOLECULAR PROFILE

CLINICAL HISTORY: ...LMP: N/A

SOURCE: APTIMA SWAB/MULTITEST

DESCRIPTIVE INFORMATION: **The in vitro Molecular Profile is a target amplification nucleic acid probe that utilizes isothermal transcription-mediated amplification (TMA) of RNA.**

Molecular Test Results

HPV HIGH RISK:	Negative
CHLAMYDIA TRACHOMATIS:	**POSITIVE**
NEISSERIA GONORRHOEAE:	Negative
TRICHOMONAS VAGINALIS:	Negative
BACTERIAL VAGINOSIS:	**POSITIVE**
* HSV1:	Negative
* HSV2:	**POSITIVE**

BACTERIAL VAGINOSIS: **POSITIVE**

The APTIMA BV Assay detects and discriminates RNA markers from the Lactobacillus species group (L. gasseri, L. crispatus and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae in clinician-collected and patient-collected vaginal swab specimens from symptomatic females with a clinical presentation consistent with vaginitis and/or vaginosis. The Aptima BV assay uses an algorithm to report a qualitative result for BV based on detection of target organisms. Performance with specimens other than those listed has not been evaluated and results must be interpreted with caution and correlated with clinical findings. The performance of this assay has not been evaluated in persons less than 14 years of age.

CANDIDA SPECIES:	**POSITIVE**
CANDIDA GLABRATA:	**POSITIVE**

* Indicates this result was tested by ProPath, 1355 River Bend Drive, Dallas, Tx 75247. The results of these tests should only be interpreted in conjunction with information available from clinical evaluation of the patient history. A negative result, interpreted on its own, does not necessarily rule out an infection. These tests are dependent on collection methods, patient factors, stage of infection and the presence of interfering substances. Please refer to www.clinicalpathologyassociates.com/women-s-health for intended uses, limitations and acceptable specimen types for these tests. The clinician must determine the use and relevance of the results of these tests when ordering outside of these parameters and results should be interpreted with caution.

CLINICAL PATHOLOGY ASSOCIATES

1150 North 18th STE 102 Abilene, TX, 79601, 325-670-6500 1-800-478-9341, CLIA 45D0508312

LAB REPORT

Accession #: OP2099999

Patient: DUCKOP, DONALD

DOB: 1/20/1980 Age: 39 Sex: Female

Specimen Date: 1/17/2020

Date Received: 1/18/2020

Date Printed: 11/12/2024

JAMES I. DUFF, M.D.
1150 N. 18TH, STE 102
ABILENE, TX 79601

TRICHOMONAS VAGINALIS: **POSITIVE**

The APTIMA CV/TV Assay detects RNA from microorganisms associated with vulvovaginal candidiasis and trichomoniasis in clinician-collected and patient-collected vaginal swab specimens from females with a clinical presentation consistent with vaginitis or vulvovaginitis. The Aptima CV/TV assay differentiates between Candida glabrata, the Candida species group (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis) and Trichomonas vaginalis. The assay does not differentiate among C spp. Performance with specimens other than those listed has not been evaluated and results must be interpreted with caution and correlated with clinical findings. The performance of this assay has not been evaluated in persons less than 14 years of age.

Internal Test Information

The FDA-approved Hologic APTIMA HPV Assay is designed to detect E6/E7 mRNA from high risk types 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 66, and 68 in cervical specimens in ThinPrep Pap Test vials collected with broom-type or cytobrush/spatula. APTIMA HPV Genotyping Assay detects for 16 and 18/45. Types 16 and 18/45 are responsible for over 80% of all invasive cervical cancers, 75% of squamous carcinomas, and 80-94% of adenocarcinomas. Performance with specimens other than those listed has not been evaluated and results must be interpreted with caution and correlated with clinical findings. The performance of this assay has not been evaluated in persons less than 14 years of age. Please see www.clinicalpathologyassociates.com/women-s-health for more information.

The FDA-approved Hologic APTIMA COMBO 2 Assay is designed to detect the presence of Chlamydia and Neisseria in the following specimens collected in Aptima transport media or PreservCyt Solution: endocervical and male urethral specimens, clinician collected vaginal swab specimens, PreservCyt Solution liquid Pap specimens, female and male urine specimens. The performance of this assay has not been evaluated in persons less than 14 years of age. Performance with specimens other than those listed has not been evaluated and results must be interpreted with caution and correlated with clinical findings.

The FDA-approved Hologic APTIMA Trichomonas vaginalis Assay is designed to detect the presence of T. vaginalis in the following specimens collected in Aptima transport media or PreservCyt Solution: clinician-collected endocervical and vaginal swab specimens, and PreservCyt liquid Pap specimens. Note: The performance of this assay has not been evaluated in persons less than 14 years of age. Performance of this test with specimens other than those listed above has not been evaluated and results must be interpreted with caution and correlated with clinical findings.

The FDA-approved Hologic APTIMA BV Assay detects and discriminates RNA markers from the Lactobacillus species group (L. gasseri, L. crispatus and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae in clinician-collected and patient-collected vaginal swab specimens from symptomatic females with a clinical presentation consistent with vaginitis and/or vaginosis. The Aptima BV assay uses an algorithm to report a qualitative result for BV based on detection of target organisms. The performance of this assay has not been evaluated in persons less than 14 years of age. Performance with specimens other than those listed has not been evaluated and results must be interpreted with caution and correlated with clinical findings.

A negative result indicates that HSV type 1 and type 2 DNA is not present at detectable quantities in this specimen. It does not indicate that this individual has never been exposed to HSV -1 and/or -2, and does not exclude the possibility of latent infection. Method: Real-time PCR. This test was developed and its performance characteristics determined by ProPath Services, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or

* Indicates this result was tested by ProPath, 1355 River Bend Drive, Dallas, Tx 75247. The results of these tests should only be interpreted in conjunction with information available from clinical evaluation of the patient history. A negative result, interpreted on its own, does not necessarily rule out an infection. These tests are dependent on collection methods, patient factors, stage of infection and the presence of interfering substances. Please refer to www.clinicalpathologyassociates.com/women-s-health for intended uses, limitations and acceptable specimen types for these tests. The clinician must determine the use and relevance of the results of these tests when ordering outside of these parameters and results should be interpreted with caution.

CLINICAL PATHOLOGY ASSOCIATES

1150 North 18th STE 102 Abilene, TX, 79601, 325-670-6500 1-800-478-9341, CLIA 45D0508312

LAB REPORT

Accession #: OP2099999

Patient: DUCKOP, DONALD

DOB: 1/20/1980 Age: 39 Sex: Female

Specimen Date: 1/17/2020

Date Received: 1/18/2020

Date Printed: 11/12/2024

JAMES I. DUFF, M.D.
1150 N. 18TH, STE 102
ABILENE, TX 79601

for research.

Entered By: JID

David P. Stanley, M.D.
11/17/2021
Electronic signature approved by pathologist.

* Indicates this result was tested by ProPath, 1355 River Bend Drive, Dallas, Tx 75247. The results of these tests should only be interpreted in conjunction with information available from clinical evaluation of the patient history. A negative result, interpreted on its own, does not necessarily rule out an infection. These tests are dependent on collection methods, patient factors, stage of infection and the presence of interfering substances. Please refer to www.clinicalpathologyassociates.com/women-s-health for intended uses, limitations and acceptable specimen types for these tests. The clinician must determine the use and relevance of the results of these tests when ordering outside of these parameters and results should be interpreted with caution.